1078 
Treatment Rates and Eligibility in HCV Mono-infected vs HCV/HIV Co-infected Persons
A Butt1,2, J Tsevat3, O Shaikh1, D McMahon1, Uzma Khan*4, Z Dorey-Stein5, and V Lo Re5
1Univ of Pittsburgh Med Ctr, PA, US; 2Ctr for Hlth Equity Res and Promotion, Pittsburgh, PA, US; 3Inst for the Study of Hlth, Univ of Cincinnati Med Ctr and Cincinnati VAMC, OH, US; 4Albany Med Ctr, NY, US; and 5Univ of Pennsylvania Med Ctr, Philadelphia, US
Background: Treatment eligibility and rates for hepatitis
C virus (HCV) infection have not been compared directly between patients with
HCV mono-infection and HCV/HIV co-infection in academic center settings. These
data are important for planning future interventions to optimize HCV treatment
patterns in these groups.
Methods: We prospectively enrolled subjects with HCV
mono-infection and HCV/HIV co-infection at 3 academic medical centers to
determine the treatment rates and eligibility for HCV in the 2 groups according
to the current treatment guidelines. Data were obtained through structured
subject and provider interviews and medical records.
Results: We enrolled 241 HCV-mono-infected and 158
HCV/HIV-co-infected subjects. The 2 groups were similar in age, but there were
more blacks (58.9% vs 30.7%, p <0.001) and males (81.6% vs 58.5%, p
<0.001) in the HCV/HIV-co-infected group. HCV/HIV-co-infected subjects
were less likely to be eligible for treatment (11.4% vs 22.7%, p = 0.001),
undergo a liver biopsy (43.7% vs 71.4%, p <0.001), and receive treatment
even when eligible (27.8% vs 73.7%, p <0.001). In multivariable analysis,
black race (OR 0.44, 95%CI 0.28 to 0.70) and HIV co-infection (OR 0.33, 95%CI
0.21 to 0.53) were independently associated with non-prescription of treatment.
Conclusions: HCV/HIV-co-infected persons are more
likely to be ineligible for treatment than HCV-mono-infected persons. Even when
eligible for treatment, they are less likely to receive treatment. Black race
and HIV co-infection are associated with a lower likelihood of treatment for
HCV.
|
